tbuckley/cabot-search huggingface dataset:
Endoscopic biliary recanalization with a needle-knife in post liver-transplant complete anastomotic stricture
Authors: F. Martins, G. De Paulo, E. Macedo, A. Ferrari
Journal: Endoscopy (2012)

Biliary strictures are challenging situations in post liver-transplant patients, occurring in up to 15 % after deceased orthotropic liver transplant (OLT) and 32 % after living donor liver transplant [1]. Endoscopic treatment is established as first-line therapy for these patients, more recently using fully covered self-expandable metallic stents (FCSEMS) [2].
SP0004 How to Assess Disease Activity and Severity in Clinical Practice
Authors: O. Fitzgerald
Journal: Annals of the Rheumatic Diseases (2013)

<h3></h3> Psoriatic Arthritis (PsA) is a complex multisystem disease with involvement of synovial structures, entheseal sites, spine, and skin and nails all common features. The extended clinical phenotype has recently received some attention with obesity, hypertension, Type 2 Diabetes Mellitus, hypercholesterolemia and metabolic syndrome all found more frequently in PsA as compared to controls. An excess of cardiovascular-related events including early mortality is a likely consequence. Radiographic change is also heterogeneous with features including erosive disease and osteolysis and also new bone formation, sacroiliitis and ankylosis. Disease activity measures in PsA have either focused on joint or skin disease or have been borrowed from rheumatoid arthritis. The Psoriatic Arthritis Response Criteria (PsARC) was developed as a specific PsA response measure but the measure is dichotomous and poorly discriminates responders from placebo. More recently, a number of composite disease activity measures have been proposed. These measures are designed to capture disease activity across all of the involved domains; as not all domains are active in all individuals with PsA and as there may be a differential treatment response, ideally it should also be possible to access disease activity and response in individual domains as well. The individual composite measures and their relative performance in clinical trial data to date will be presented and discussed. Measuring disease severity may well relate to disease activity but this is yet to be clearly demonstrated. There would be little argument with the statement that patients with the arthritis mutilans phenotype have severe disease but there are many patients with polyarticular disease and high inflammatory markers who do not develop this severe phenotype. Severe disease whether it is defined on the basis of radiographic change, severe skin/nail disease, some of the cardiovascular risk factors such as presence of the metabolic syndrome or even some composite score requires further study in order to identify as early as possible risk factors which predict its development. Some recent results based on analysis of detailed clinical and genetic data will be presented. If risk factors are modifiable or if early treatment intervention for patients with potentially severe disease can bring about a change in outcome, then some progress for PsA patients will have been made. <h3>Disclosure of Interest</h3> O. Fitzgerald Grant/research support from: Pfizer, Abbott, BMS, Roche, Merck
Case 26-1984
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, George P. Canellos, Eugene J. Mark
Journal: New England Journal of Medicine (1984)

Presentation of CaseA 53-year-old woman was admitted to the hospital because of acute hemolytic anemia.She was well until 101/2 years earlier, when a mass was found in the left breast. A left radical mastectomy was performed. Microscopical examination of the excised specimen disclosed adenocarcinoma, with metastases to five lymph nodes. Postoperative radiation treatment was administered to the chest wall and axillary area. Lymphedema of the left arm developed. Nine years before admission recurrent tumor was found in the chest wall, and bilateral oophorectomy was performed. Three years later right axillary lymphadenopathy developed. Microscopical examination of a biopsy specimen . . .
Focal Pyelonephritis
Authors: JOHN R. STY, MARIO E. RUIZ, ROBERT G. WELLS
Journal: Clinical Nuclear Medicine (1996)

A 5-year-old black girl with sickle cell anemia had back pain with an associated fever. The clinical diagnosis was bone infarction or osteomyelitis of the spine. A radionuclide bone scan was performed and demonstrated extraosseous uptake in the spleen, which is a common finding in patients with sickle cell anemia. However, in addition, a focal area of abnormal activity in the midupper portion of the right kidney was demonstrated. An ultrasound examination was performed that demonstrated a focal hyperechoic area at the same site. Urine analysis demonstrated an acute pyelonephritis. The child was treated with antibiotics and promptly responded.
1216 ACCESS TO HCV TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR WITH PEGINTERFERON RIBAVIRIN IN REAL LIFE SETTING IN HIV–HCV CO-INFECTED PATIENTS – ANRS CO13 Hepavih COHORT
Authors: I. Poizot-Martin, L. Merchadou, P. Carrieri, P. Miailhes, S. Domingues, F. Dabis, P. Sogni, M.-A. Loko, D. Salmon
Journal: Journal of Hepatology (2013)
IS THERE A DIFFERENCE IN TACHYCARDIA CYCLE LENGTH DURING SUPRAVENTRICULAR TACHYCARDIA IN CHILDREN WITH ATRIO-VENTRICULAR RECIPROCATING TACHYCARDIA AND ATRIO-VENTRICULAR NODAL RE-ENTRY TACHYCARDIA?
Authors: Marcos Mills, Kara Motonaga, Anthony Trela, Anne Dubin, Kishor Avasarala, Scott Ceresnak
Journal: Journal of the American College of Cardiology (2016)
P1320 ASSESSMENT OF ACUTE KIDNEY INJURY IN ADVANCED LIVER CIRRHOSIS: AKIN VERSUS CONVENTIONAL CRITERIA AND OUTCOME POST-LIVER TRANSPLANTATION
Authors: F. Fiacco, F. Tinti, I. Umbro, P. Piselli, A. Zavatto, S. Ginanni Corradini, M. Rossi, L. Poli, P.B. Berloco, A.P. Mitterhofer
Journal: Journal of Hepatology (2014)
Abstract LB-379: Combating trastuzumab resistance by targeting Src, a common node downstream of multiple resistance pathways
Authors: Siyuan Zhang, Wen-Chien Huang, Ping Li, Hua Guo, Say-Bee Poh, Samuel Brady, Yan Xiong, Ling-Ming Tseng, Shau-Hsuan Li, Zhaoxi Ding, Aysegul Sahin, Francisco Esteva, Gabriel Hortobagyi, Dihua Yu
Journal: Cancer Research (2011)

Abstract Objective of the study: Trastuzumab is a highly successful example of rationally designed ERBB2-targeted therapy. However, about half of patients with ERBB2-overexpressing breast cancer do not respond to trastuzumab-based therapies due to various resistance mechanisms. Clinically applicable regimens for overcoming trastuzumab resistance of different mechanisms are not yet available. The objective of the study is to find a common key node of multiple trastuzumab resistance mechanisms and design a clinical applicable strategy to target this common node to more effectively overcome trastuzumab resistance. Methodology: First, we evaluated Src activity in multiple acquired and de novo trastuzumab-resistant cell lines models. Cells with modulated Src activity were examined for trastuzumab resistance in vitro and in an orthotopic xenograft model. Moreover, tumors from patients receiving trastuzumab therapy were also analyzed retrospectively for clinical correlation of Src activity with trastuzumab response. Src activated trastuzumab-resistant cells were further treated with Src inhibitor (saracatinib), trastuzumab, or a combination of both in vitro and in vivo. Results: We demonstrate that the non-receptor tyrosine kinase Src serves as a critical modulator of trastuzumab response and a common node downstream of multiple trastuzumab resistance pathways. Src is activated in both acquired and de novo trastuzumab-resistant cells. Increased Src activation conferred significant trastuzumab resistance (P = 0.011) in breast cancer cells and correlated with trastuzumab resistance in patients. Targeting the common node Src in combination with trastuzumab universally sensitized multiple lines of trastuzumab-resistant cells to trastuzumab and eliminated trastuzumab-resistant tumors in vivo. Targeting Src, a critical convergence point of divergent trastuzumab resistance mechanisms, represents a highly effective and clinically convenient strategy to overcome trastuzumab resistance. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-379. doi:10.1158/1538-7445.AM2011-LB-379
Effect of Fluid Administration on the Development of Symptomatic Patent Ductus Arteriosus and Congestive Heart Failure in Premature Infants
Authors: Edward F. Bell, David Warburton, Barbara S. Stonestreet, William Oh
Journal: New England Journal of Medicine (1980)

We studied 170 premature infants with birth weights between 751 and 2000 g in a randomized sequential trial comparing "high" and "low" volumes of fluid intake. Beginning on the third day of life, the low-volume group received only enough water to meet average estimated requirements, and the high-volume group received an excess of at least 20 ml per kilogram of body weight per day (mean excess, 47 ml per kilogram per day). Sequential analysis showed that the risk of patent ductus arteriosus with congestive heart failure was greater in infants receiving the high-volume regimen. Thirty-five of 85 infants in the high-volume group acquired murmurs consistent with patent ductus arteriosus, and 11 of these 35 had congestive heart failure. Only nine of 85 infants in the low-volume group had murmurs consistent with patent ductus arteriosus, and two of these nine had congestive heart failure. More cases of necrotizing enterocolitis also occurred in the high-volume group. We conclude that limitation of fluid intake to amounts estimated to meet requirements for excretion, insensible loss, and growth can reduce the risks of patent ductus arteriosus and congestive heart failure in premature infants.
Hypoalbuminemia as a risk factor of interstitial lung disease (ILD) during gefitinib treatment in patients with non-small cell lung cancer (NSCLC): A JMTO study
Authors: M. Nakagawa, S. Teramukai, H. Tada, K. Furuse, F. Tanaka, T. Mio, M. Mishima, H. Wada, M. Fukushima
Journal: Journal of Clinical Oncology (2005)

7190 Backgrounds: Drug-induced deaths due to ILD associated with gefitinib have been reported after the approval in Japan on July 2002, and the number of deaths reached in total 295 cases (ILD: 285 cases) in July 2003. The high incidence and fatality of ILD became a serious social issue in Japan. To clarify the risk factors of adverse events, especially of ILD, associated with the use of gefitinib, we conducted a retrospective survey. Methods: We retrospectively reviewed the patient’s characteristics and clinical information accompanied with treatment of gefitinib from Jul 1 2002 to Feb 28 2003, using the questionnaires delivered to 45 institutions. Results: Twenty (44%) institutions replied with information containing a total of 409 patients, and 399 were eligible for analysis. Patients characteristics were as follows; male/female: 64%/36%, ad./others: 67%/33%, mean age: 66.8 (range; 27–91), and ECOG PS0–1/2–4: 65%/35%. ILD develop in 33 patients (8.3%, 95%CI: 5.8–11.4%), and 17 (51.5%) had died of the disease. We performed a multivariate analysis using 283 patient’s detailed information containing 27 patients developing ILD. The logistic regression analysis indicated that the predictors of ILD developing (p < 0.1) were decrease of serum albumin (odds ratio: 4.9 per 1g/dl, 95%CI: 2.2–10.9), concomitant radiotherapy (3.6, 95%CI: 1.1–11.5), history of interstitial pneumonitis (4.3, 95%CI: 1.0–18.9), and absence of history of chemotherapy (0.4, 95%CI: 0.2–1.1). The response rate was 19.6% (95%CI: 15.5–24.4) consisted of 4 CR and 60 PR, in 326 evaluable patients. Conclusions: The results of this study suggested the importance of serum albumin as the risk factor of ILD associated with the use of gefitinib. Physicians should carefully prescribe for gefitinib and monitor patients considering the risk factors, especially for patients with low serum albumin and lung-related complications. No significant financial relationships to disclose.
Same-Day Discharge After Percutaneous Coronary Intervention
Authors: Adhir Shroff, Joel Kupfer, Ian C. Gilchrist, Ronald Caputo, Bernadette Speiser, Olivier F. Bertrand, Samir B. Pancholy, Sunil V. Rao
Journal: JAMA Cardiology (2016)

<h3>Importance</h3> The evolution of percutaneous coronary intervention (PCI) has led to improved safety and efficacy, such that overnight observation can be avoided in some patients. We sought to provide a narrative review of the current literature regarding the outcomes of same-day discharge (SDD) PCI and to describe a framework for the development of an SDD program. <h3>Observations</h3> A literature search of PubMed was performed for human studies on SDD PCI published in English from January 1, 1995, to July 31, 2015. We reviewed the studies between June and September 2015. After literature review, we included reports of randomized clinical trials, observational studies, meta-analyses guidelines, and consensus statements in a narrative review. Compared with overnight observation, there was no increase in adverse events (bleeding, repeat coronary procedures, death, or rehospitalization) among patients in these studies who were discharged on the same day of their PCI procedure. Same-day discharge was associated with significant cost savings and was preferred by patients. <h3>Conclusions and Relevance</h3> The available evidence supports the safety of SDD in selected patients after PCI. Specific programmatic features are important to the successful implementation of SDD after PCI. Greater adoption of SDD programs after PCI has the potential to improve patient satisfaction, increase bed availability, and reduce hospital costs without increasing adverse patient outcomes.
Meckel's Diverticulum
Authors: HAROLD B. HAWKINS, JAMES D. SLAVIN, ROLINA LEVIN, RICHARD P. SPENCER
Journal: Clinical Nuclear Medicine (1996)

The results from an ultrasound study performed on an 11-year-old boy, who had several weeks of intermittent abdominal pain, showed a nonperistaltic loop of bowel near the umbilicus, which suggested either an internal hernia or a diverticulum. Tc-99m pertechnetate imaging showed a focal collection near the umbilicus, which was consistent with a Meckel's diverticulum. No evidence was found of gastrointestinal bleeding. Exploratory laparotomy showed a Meckel's diverticulum near the terminal ileum and attached to the anterior abdominal wall close to the umbilicus. Small bowel had herniated through the loop formed by the terminal ileum and the diverticulum.
CEO pay at US non-profit hospitals not associated with quality or charity care, study finds
Authors: M. McCarthy
Journal: BMJ (2013)

Compensation for chief executive officers (CEOs) at non-profit hospitals in the United States are associated with the hospitals’ patient satisfaction ratings and employment of high technology, but not with their performance on quality measures, financial strength, or provision of charity care, a new study has found.1

In the study, published online in the journal JAMA Internal Medicine , Karen E Joynt, of the Harvard School of Public Health in Boston, Massachusetts, and colleagues, analyzed data available from the 2009 tax returns of US hospitals filing as non-profit entities.

They identified 1877 chief executive officers overseeing 2681 non-federal, private, non-profit hospitals in the US, accounting for 98% of private non-profit hospitals operating in the country.

They then looked to see to what degree the hospitals’ compensation packages for their CEOs were associated with various characteristics, such as the hospital size and whether they were teaching hospitals, and, after adjusting …
P582 GRP78 POLYMORPHISM rs430397 IS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN A SOUTHERN ITALIAN POPULATION
Authors: D. Balasus, L. Giannitrapani, M. Soresi, M. Vinciguerra, M. Marsha, M. Way, A. Licata, M. Cervello, G. Montalto
Journal: Journal of Hepatology (2014)
Positive Relationship Between Expression of Anti-metastatic Factor (nm23 Gene Product or Nucleoside Diphosphate Kinase) and Good Prognosis in Human Breast Cancer
Authors: R Hirayama, S Sawai, Y Takagi, Y Mishima, N Kimura, N Shimada, Y Esaki, C Kurashima, M Utsuyama, K Hirokawa
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Positive Relationship Between Expression of Anti-metastatic Factor (nm23 Gene Product or Nucleoside Diphosphate Kinase) and Good Prognosis in Human Breast Cancer Get access Renzo Hirayama, Renzo Hirayama Search for other works by this author on: Oxford Academic PubMed Google Scholar Shigeo Sawai, Shigeo Sawai Search for other works by this author on: Oxford Academic PubMed Google Scholar Yoko Takagi, Yoko Takagi Search for other works by this author on: Oxford Academic PubMed Google Scholar Yoshio Mishima, Yoshio Mishima Search for other works by this author on: Oxford Academic PubMed Google Scholar Narimichi Kimura, Narimichi Kimura Search for other works by this author on: Oxford Academic PubMed Google Scholar Nobuko Shimada, Nobuko Shimada Search for other works by this author on: Oxford Academic PubMed Google Scholar Yukiyoshi Esaki, Yukiyoshi Esaki Search for other works by this author on: Oxford Academic PubMed Google Scholar Chieri Kurashima, Chieri Kurashima Search for other works by this author on: Oxford Academic PubMed Google Scholar Masanori Utsuyama, Masanori Utsuyama Search for other works by this author on: Oxford Academic PubMed Google Scholar Katsuiku Hirokawa Katsuiku Hirokawa Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 17, 4 September 1991, Pages 1249–1250, https://doi.org/10.1093/jnci/83.17.1249 Published: 04 September 1991 Article history Received: 18 March 1991 Revision received: 20 May 1991 Accepted: 29 May 1991 Published: 04 September 1991
Reply to A. Berruti et al
Authors: Irina Veytsman, Tito Fojo
Journal: Journal of Clinical Oncology (2010)

We thank Berruti et al 1 for their correspondence.We recommended that adjuvant mitotane therapy be used only in patients with a high likelihood of recurrence-that is, patients with large tumors with many of the features that comprise the Weiss score and small or questionable surgical margins.The panel's recommendation cited in the correspondence states that mitotane should be offered to patients with potential residual disease (R1 or Rx resection) and/or Ki67 more than 10%.We would agree with the panel's recommendation, considering that it is similar to our suggestion, although we place less emphasis on Ki67, choosing instead to take a more comprehensive view.Receiving treatment with mitotane also depends on the patient's preference and the patient's tolerability of this difficult therapy; however, ensuring careful, frequent follow-up to detect a local recurrence as early as possible is essential.
Abstract 2098: Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells.
Authors: Stacy L. Wempe, Carlos D. Gamarra-Luques, Carlos M. Telleria
Journal: Cancer Research (2013)

Abstract We have previously shown that the antiprogestin/antiglucocorticoid mifepristone inhibits the growth of ovarian cancer cells. In this work, we hypothesized that cellular stress caused by mifepristone is limited to cytostasis and that cell killing is avoided because of a compensatory activation of the PI3K/Akt survival pathway.To investigate the role of this pathway in mifepristone-induced growth inhibition, human ovarian cancer cells of various histological subtypes and genetic backgrounds were exposed to cytostatic doses of mifepristone in the presence or absence of the PI3K inhibitor, LY294002. Mifepristone-induced growth arrest of ovarian cancer cells was associated with phosphorylation of Akt (Ser473), which was prevented by treatment with LY294002. The combination mifepristone/LY294002, but not the individual drugs, killed ovarian cancer cells via apoptosis, as attested by genomic DNA fragmentation and cleavage of caspase-3, and the concomitant downregulation of anti-apoptotic proteins Bcl-2 and XIAP. From a pharmacological standpoint, when assessing cell growth inhibition using a median-dose analysis algorithm, the interaction between mifepristone and LY294002 was synergistic. The lethality caused by the combination mifepristone/LY294004 in two dimensional cell cultures was recapitulated in organized, tri-dimensional spheroids. This study demonstrates that mifepristone and LY294002, when used individually cause cell growth arrest, yet when combined, they cause lethality. This work further provides proof-of-concept that in combination, targeted cytostatic therapies can be an efficient tool to engage cancer cells in a death program. Citation Format: Stacy L. Wempe, Carlos D. Gamarra-Luques, Carlos M. Telleria. Synergistic lethality of mifepristone and LY294002 in ovarian cancer cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2098. doi:10.1158/1538-7445.AM2013-2098
Long-Term Outcome of Hepatitis C Infection after Liver Transplantation
Authors: Edward J. Gane, Bernard C. Portmann, Nikolai V. Naoumov, Heather M. Smith, James A. Underhill, Peter T. Donaldson, Geert Maertens, Roger Williams
Journal: New England Journal of Medicine (1996)

End-stage cirrhosis related to hepatitic C virus (HCV) is a common reason for liver transplantation, although viremia ia known to persist in most cases. We investigated the impact of persistent HCV infection after liver transplantation on patient and graft survival and the effects of the HCV genotype and the degree of HLA matching between donor and recipient on the severity of recurrent hepatitis.A group of 149 patients with HCV infection who received liver transplants between January 1982 and April 1994 were followed for a median of 36 months; 623 patients without HCV infection who underwent liver transplantation for end-stage chronic liver disease were used as a control group. A total of 528 liver-biopsy specimens from the HCV-infected recipients were reviewed, including 82 obtained one year after transplantation as scheduled and 39 obtained at five years as scheduled. In addition, biopsy specimens were obtained from 91 of the HCV-negative patients five years after transplantation.Cumulative survival rates for the 149 patients with HCV infection were 79 percent after one year, 74 percent after three years, and 70 percent after five years, as compared with rates of 75 percent, 71 percent, and 69 percent, respectively, in the HCV-negative transplant recipients (P=0.12). Of the 130 patients with hepatitis C infection who survived more than 6 months after transplantation, 15 (12 percent) had no evidence of chronic hepatitis on their most recent liver biopsy (median followup, 20 months), 70 (54 percent) had mild chronic hepatitis (median, 35 months), 35 (27 percent) had moderate chronic hepatitis (median, 35 months), and 10 (8 percent) had cirrhosis (median, 51 months). Graft loss occurred after a median of 303 days in 27 of the 149 patients, including 5 with HCV-related cirrhosis and 3 with HCV-related cholestatic hepatitis. Infection with HCV genotype 1b was associated with more severe graft injury, whereas the primary immunosuppressive regimen used and the extent of HLA mismatching between donors and recipients had no significant effect on this variable.After liver transplantation for HCV-related cirrhosis, persistent HCV infection can cause severe graft damage, and such damage is more frequent in patients infected with HCV genotype 1b than with other genotypes. After five years, the rates of graft and overall survival are similar between patients with and those without HCV infection.